Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Current data of hepatitis B virus (HBV) variants associated with treatment outcome identified by next generation sequencing (NGS) are limited. This study was aimed at determining the role of baseline sequence variations in the enhancer II (EnhII), basal core promotor (BCP) and pre-core (PC) regions of HBV genotype C in patients treated with pegylated interferon (PEG-IFN). Patients with HBeAg-positive chronic hepatitis B (CHB) treated with 48-week PEG-IFN were enrolled. Combined response (CR) at week 96 was defined by HBeAg seroconversion plus HBV DNA 

Original publication




Journal article


Virus genes

Publication Date





610 - 618


Faculty of Medicine, Center of Excellence in Hepatitis and Liver Cancer, Chulalongkorn University, Bangkok, Thailand.


Humans, Hepatitis B virus, Hepatitis B, Chronic, Interferons, Hepatitis B Core Antigens, Hepatitis B e Antigens, Antiviral Agents, Treatment Outcome, Prevalence, Genotype, Mutation, Adolescent, Adult, Middle Aged, Female, Male, Promoter Regions, Genetic, Genetic Variation, Young Adult, High-Throughput Nucleotide Sequencing